Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Ma

Critical Care Medicine Philadelphia, PA Medical Doctor

NPI 1013216357 CMS profile 1389610

3400 Spruce St, 3 Ravdin, Philadelphia, PA 19104

Open in the dashboard

General payments

$14,814

61 records reported · program years 2019–2025

Research payments

$2,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$177,285 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Kevin Ma of Philadelphia, PA is reported in the CMS Open Payments database as having received $14,814 across 61 general payments and $2,000 in research payments paid to them. Separately, studies naming them as principal investigator received $177,285 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,462 15
2024 General $3,763 21
2024 Research $2,000 1
2023 General $4,517 15
2022 General $3,860 6
2021 General $46 2
2019 General $166 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Ma
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Kevin Ma were reported at $2,462. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Kevin Ma Critical Care Medicine median Middle half National median
2019 $166 $149 $51–$535 $163
2020 $0 $110 $30–$325 $114
2021 $46 $125 $34–$403 $132
2022 $3,860 $157 $49–$582 $149
2023 $4,517 $162 $56–$621 $160
2024 $3,763 $168 $53–$634 $164
2025 $2,462 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pulmonx Corporation $6,973 27 payments
  2. Intuitive Surgical, Inc. $6,601 21 payments
  3. Merit Medical Systems Inc $355 2 payments
  4. Verona Pharma, Inc. $290 2 payments
  5. Ethicon Inc. $251 4 payments
  6. Siemens Medical Solutions USA, Inc. $196 1 payment
  7. Medical Device Business Services, Inc. $45 1 payment
  8. Olympus America Inc. $45 1 payment
  9. Genzyme Corporation $43 1 payment
  10. Galvanize Therapeutics, Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,313 5 payments
  2. Education $4,214 6 payments
  3. Food and Beverage $3,364 43 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 2 payments
  5. Travel and Lodging $923 5 payments
Products named General payments · program years 2019–2025
  1. ZEPHYR ENDOBRONCHIAL VALVE $6,958 26 payments
  2. CHARTIS CATHETER $5,120 24 payments
  3. ZEPHYR DELIVERY CATHETER $5,120 24 payments
  4. PULMONX CHARTIS TABLET CONSOLE $5,120 24 payments
  5. Da Vinci Surgical System $3,601 20 payments
  6. ION $3,000 1 payment
  7. AEROflex $350 1 payment
  8. Cryo BX $350 1 payment
  9. Ohtuvayre $290 2 payments
  10. Cios Spin $196 1 payment
  11. Other $419 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Optellum Ltd $2,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

149

Median for Critical Care (Intensivists): 406

Drug cost

$37,664

Median for Critical Care (Intensivists): $197,260

Branded share of claims

56.4%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 25 $18,202
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $8,494
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 16 $7,013
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 16 $2,507
Azithromycin Generic 31 $699
Albuterol Sulfate Hfa Albuterol Sulfate Brand 14 $509
Montelukast Sodium Generic 18 $212
Prednisone Generic 16 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$58,672

Medicare's payments for the services billed

Medicare patients

237

Average age 72

Services billed

726

121 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 54%
COPD 53%
Arthritis 38%
Ischemic heart disease 35%
Chronic kidney disease 30%
Diabetes 29%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record